Journal of Medical Economics
Volume 26, 2023 - Issue 1
Oncology
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan
Takashi Mizuokaa Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0009-0009-1668-9993
https://orcid.org/0009-0009-1668-9993, , Shigeo Fujic Department of Hematology, Osaka International Cancer Institute, Osaka, Japanhttps://orcid.org/0000-0001-5118-7950
https://orcid.org/0000-0001-5118-7950, , , Shinya Ohnoa Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japanhttps://orcid.org/0000-0002-4157-9165
https://orcid.org/0000-0002-4157-9165, Naoki Inubashiria Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japanhttps://orcid.org/0009-0005-9179-9800
https://orcid.org/0009-0005-9179-9800, Tomoha Oshimaa Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japanhttps://orcid.org/0009-0005-1317-0425
https://orcid.org/0009-0005-1317-0425 & Kazuhito Yamamotoe Aichi Cancer Center, Aichi, Japanhttps://orcid.org/0000-0002-8588-8955
https://orcid.org/0000-0002-8588-8955 show all